PROGRAM CHAIR
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer, Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, DC
SPEAKING FACULTY
Richard F. Dunne, MD, MS
Associate Professor of Medicine
Section Leader, Gastrointestinal Cancer Unit
Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, NY
PROGRAM OVERVIEW
This enduring Grand Rounds program is focused on advanced, HER2-expressing gastric cancer (GC) or gastroesophageal junction (GEJ) cancers. It will update you on best practices related to HER2 expression testing in this setting, provide a critical review of relevant clinical trial findings, and offer practical guidance on multidisciplinary monitoring and management of treatment-related adverse events in patients receiving a HER2-directed therapy for GC or GEJ cancer. This interactive program combines didactic instruction with case-based discussions and animations.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community medical oncologists and multidisciplinary team members involved in the management of patients with gastric and gastroesophageal junction cancers.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Discuss current best practices informing the assessment of HER2 expression in patients with advanced gastric or gastroesophageal junction (GEJ) cancers
- Analyze clinical data informing the use of HER2-directed antibody-drug conjugate therapy in the management of advanced gastric and GEJ cancers
- Review best practices in appropriate monitoring and mitigation of potential adverse events associated with HER2-targeted antibody-drug conjugate therapies, including interstitial lung disease and pneumonitis
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| John L. Marshall, MD | Discloses receiving consulting fees and serving on the speakers’ bureaus for: AstraZeneca, Merck, Bayer, Taiho Pharmaceutical, Pfizer, Seagen, Arcus Biosciences, Takeda Pharmaceutical, Astellas Pharma, and Caris Life Sciences. |
| Richard F. Dunne, MD | Discloses serving as a consultant for Toray Industries, Inc., Merck & Co., Exelixis Inc. and Pfizer Inc. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP of Educational Development for Med Learning Group, has nothing to disclose.
- Kim Farina, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Sarah Milano RN, MSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 12, 2024
EXPIRATION DATE: December 12, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
